1. Show article details.

    Meridian Bioscience to Participate in the 40th Annual William Blair Growth Stock Conference

    GlobeNewswire – 8:00 AM ET 05/29/2020

    Meridian Bioscience, Inc. (VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the 40th Annual William Blair Growth Stock Conference on Tuesday, June 9, 2020 at 8:40 AM CT. To access the live webcast, go the Events & Presentations section of the Company’s Investor Relat...

  2. Show article details.

    BRIEF-Meridian To Supply Reagents To Make Tens Of Millions Of COVID-19 Antibody Tests Per Month

    Reuters – 9:15 AM ET 05/26/2020

    Meridian Bioscience Inc (VIVO): * MERIDIAN BIOSCIENCE ANNOUNCES IT WILL SUPPLY REAGENTS FOR MANUFACTURING OF TENS OF MILLIONS OF COVID-19 ANTIBODY TESTS PER MONTH Source text for Eikon: Further company coverage:

  3. Show article details.

    Meridian Bioscience Announces It Will Supply Reagents for the Manufacturing of Tens of Millions of COVID-19 Antibody Tests Per Month

    GlobeNewswire – 8:00 AM ET 05/26/2020

    Meridian Bioscience, Inc. (VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that its SARS-CoV-2 antigens and related reagents are part of assays granted U.S. Food and Drug Administration Emergency Use Authorization, with projected production schedules of tens of millions of COVID-19 antibody tests per month.

  4. Show article details.

    Meridian Bioscience Promotes Tony Serafini-Lamanna to Executive Vice President of Diagnostics

    GlobeNewswire – 4:20 PM ET 05/20/2020

    Meridian Bioscience (VIVO), Inc.’s Board of Directors announced that Tony Serafini-Lamanna has been promoted to Executive Vice President of Diagnostics. David Phillips, Chairman of Meridian Bioscience (VIVO), said, “Jack’s leadership was critical to the strategic redirection of our Diagnostics division.

  5. Show article details.

    BRIEF-Meridian Bioscience Reports Second Quarter 2020 Operating Results Raises Guidance On Strength Of Covid-19 Related Products

    Reuters – 8:30 AM ET 05/08/2020

    Meridian Bioscience Inc (VIVO): * MERIDIAN BIOSCIENCE REPORTS SECOND QUARTER 2020 OPERATING RESULTS; RAISES GUIDANCE ON STRENGTH OF COVID-19 RELATED PRODUCTS. * Q2 REVENUE ROSE 14 PERCENT TO $57.3 MILLION. * Q2 GAAP EARNINGS PER SHARE $0.22. * RAISING FISCAL 2020 GUIDANCE. * SEES 2020 CONSOLIDATED NET REVENUES $230 MILLION TO $236 MILLION.

  6. Show article details.

    Meridian Bioscience Reports Second Quarter 2020 Operating Results; Raises Guidance on Strength of COVID-19 Related Products

    GlobeNewswire – 7:30 AM ET 05/08/2020

    Meridian Bioscience, Inc. (VIVO) today announced financial results for the second quarter ended March 31, 2020. Second Quarter Fiscal 2020 Highlights: Jack Kenny, Chief Executive Officer, commented: “We had an extraordinary quarter on many fronts, led by our Life Science team’s rapid response to the COVID-19 pandemic.

  7. Show article details.

    BRIEF-Meridian Bioscience Partners With QuantuMDx On COVID-19 Assay

    Reuters – 8:02 AM ET 05/06/2020

    Meridian Bioscience Inc (VIVO): * MERIDIAN BIOSCIENCE PARTNERS WITH QUANTUMDX ON COVID-19 ASSAY Source text for Eikon: Further company coverage:

  8. Show article details.

    Meridian Bioscience Partners with QuantuMDx on COVID-19 Assay

    GlobeNewswire – 8:00 AM ET 05/06/2020

    Meridian Bioscience, Inc. (VIVO), a leading provider of diagnostic testing solutions and life science raw materials, is pleased to announce its collaboration with QuantuMDx on its newly launched SARS-CoV-2 assay for laboratory use.

  9. Show article details.

    Meridian Bioscience Announces Closing of Transaction to Acquire Exalenz Bioscience

    GlobeNewswire – 10:50 AM ET 04/30/2020

    Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials, has completed its previously announced acquisition of Exalenz Bioscience Ltd., the Modiin, Israel based provider of the BreathID® Breath Test Systems, a urea breath test platform for the detection of Helicobacter pylori.

  10. Show article details.

    Meridian Bioscience Simplifies COVID-19 Sample Prep and Eliminates Dependence on Reagents in Short Supply

    GlobeNewswire – 11:56 AM ET 04/27/2020

    Meridian Bioscience, Inc. (VIVO) announced today the launch of a novel enzyme master mix that eliminates the need to use an RNA extraction kit prior to running the patient sample through a molecular assay. To date, most COVID-19 molecular assays require laboratories to first isolate and purify the SARS-CoV-2 viral RNA from a patient sample.

  11. Show article details.

    Meridian Bioscience To Hold Second Quarter 2020 Financial Results Conference Call On May 8, 2020

    GlobeNewswire – 9:00 AM ET 04/16/2020

    Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter 2020 financial results Friday, May 8, 2020. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions.

  12. Show article details.

    BRIEF-Meridian Bioscience offers SARS-CoV-2 antigens for COVID-19 Antibody Tests

    Reuters – 9:40 AM ET 04/14/2020

    Meridian Bioscience Inc (VIVO): * Meridian Bioscience Inc (VIVO) - ANNOUNCED LAUNCH OF SEVERAL NOVEL RECOMBINANT ANTIGENS FOR DEVELOPMENT OF ANTIBODY TESTS FOR COVID-19 Source text for Eikon: Further company coverage:

  13. Show article details.

    Meridian Bioscience offers SARS-CoV-2 antigens for COVID-19 Antibody Tests

    GlobeNewswire – 9:33 AM ET 04/14/2020

    Meridian Bioscience, Inc. (VIVO), announced today the launch of several novel recombinant antigens critical for the development of antibody tests for COVID-19. Since the emergence of COVID-19 outbreaks in January, Meridian has supported molecular diagnostic companies with critical master mixes and enzymes for their COVID-19 Molecular Diagnostics tests.

  14. Show article details.

    MERIDIAN BIOSCIENCE ANNOUNCES BETTER-THAN-EXPECTED PRELIMINARY SECOND QUARTER FISCAL 2020 REVENUE RESULTS WITH DOUBLE-DIGIT GROWTH

    GlobeNewswire – 7:30 AM ET 04/02/2020

    Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided a business update including preliminary revenue results for its second quarter of fiscal 2020.

  15. Show article details.

    Meridian Bioscience Supports Diagnostic Companies in Fighting Coronavirus Pandemic by Providing Zero Cost Proprietary Technology for Evaluation

    GlobeNewswire – 11:51 AM ET 03/16/2020

    Meridian Bioscience, Inc. (VIVO) announced today its increased commitment to the global fight against COVID-19 by making available zero cost samples of the company’s proprietary technologies to developers and manufacturers of molecular assays for COVID-19 detection.

  16. Show article details.

    Meridian Bioscience Announces FDA-Clearance for New Curian™ Analyzer and the Curian™ HpSA® Assay

    GlobeNewswire – 8:00 AM ET 03/16/2020

    Meridian Bioscience, Inc. (VIVO) a provider of immunoassay, molecular, and blood chemistry diagnostic testing solutions, today announced that it has received FDA-clearance for Meridian’s new Curian™ and Curian™ HpSA® assay. Curian and Curian HpSA are designed to quickly detect Helicobacter pylori antigens in human stool using immunofluorescent technology.

  17. Show article details.

    Meridian’s Novel Air-Dryable qPCR Mix Decreases Costs and Simplifies Workflows for Molecular Test Manufacturers

    GlobeNewswire – 8:00 AM ET 02/26/2020

    Meridian Bioscience, Inc. (VIVO), following the extremely successful launch of the Lyo-Ready qPCR mixes, is proud to introduce today its Air-Dryable qPCR Mix. Meridian’s Air-Dryable qPCR Mix has been designed to simplify assay development and workflow through a magnesium containing formulation allowing air or oven drying protocols.

  18. Show article details.

    Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform

    GlobeNewswire – 9:15 AM ET 02/19/2020

    Meridian Bioscience, Inc. (VIVO) and Exalenz Bioscience Ltd. announced today that the two companies have entered into a definitive agreement for Meridian to acquire Exalenz for ₪6.10 per share in cash with an implied transaction value of approximately $49 million.

  19. Show article details.

    Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results and Reaffirms 2020 Guidance

    GlobeNewswire – 7:30 AM ET 02/07/2020

    Meridian Bioscience, Inc. (VIVO) today announced financial results for the first quarter ended December 31, 2019.

  20. Show article details.

    Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak

    GlobeNewswire – 9:17 AM ET 01/27/2020

    Meridian Bioscience, Inc. (VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named 2019-nCoV, is a new strain that had not been previously identified in humans.

Page:

Today's and Upcoming Events

  • Aug
    03

    VIVO to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    08

    VIVO announced Q2 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.